

O I P E
JAN 12 2000
JC65
U.S. Department of Commerce
Patent and Trademark Office

Sheet 1 of 1

Substitute Form PTO-1449 (Modified)		Attorney's Docket No. 08191-008003	Application No. 09/372,380
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Roman M. Chicz et al.	
		Filing Date August 11, 1999	Group Art Unit 1643

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
<i>SFB</i>	AA	5,827,516	10/27/98	Urban et al.	424	93.21	
<i>SFB</i>	AB	5,880,103	03/09/99	Urban et al.	514	44	
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>
<i>SFB</i>	AI	WO 94/04557	03/03/94	PCT			
	AJ						
	AK						
	AL						
	AM						

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
<i>SFB</i>	AN	Chicz et al., "Analysis of MHC-presented peptides: applications in autoimmunity and vaccine Development", Immun. Today, 15:155-160, 1994
<i>SFB</i>	AQ	Claverie et al., "The Peptidic Self Model: A Reassessment of the Role of the Major Histocompatibility Complex Molecules in the Restriction of the T-Cell Response", Ann. Inst. Pasteur/Immunol., 137:425-442, 1986
<i>SFB</i>	AP	Hunt et al., "Characterization of Peptides Bound to the Class I MHC Molecule HLA A2.1 by Mass Spectrometry", Science, 255:1261-1263, 1992
<i>SFB</i>	AQ	Kourilsky et al., "The Peptidic Self Model: A Hypothesis on the Molecular Nature of the Immunological Self", Ann. Inst. Pasteur/Immunol. 137:3-21, 1986
<i>SFB</i>	AR	Kourilsky et al., "Working principles in the immune system implied by the "peptidic self" model", Proc. Natl. Acad. Sci. USA, 84:3400-3404, 1987
<i>SFB</i>	AS	Urban et al., "The Discovery and Use of HLA-Associated Epitopes as Drugs", Critical Reviews in Immunol., 17:387-397, 1997

Examiner Signature <i>D. Shulman</i>	Date Considered 3/21/01
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08191-008003	Application No. 09/372,380
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Roman M. Chicz et al.	
		Filing Date August 11, 1999	Group Art Unit 1643
(37 CFR §1.98(b))			

U.S. Patent Documents


Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5,692,181	11/25/97	Anand et al.	395	613	
	AB	5,741,653	4/21/98	Kauvar et al.	435	7.1	
	AC	5,778,363	7/7/98	Light, J.	705	5	
	AD	6,064,754	5/16/00	Parekh et al.	382	129	

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AE							
	AF							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AG	Search Report, PCT/US99/17680, April 4, 2000
	AH	
	AI	
	AJ	

Examiner Signature 	Date Considered 3/21/01
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	